Intelligent, Integrated and Autonomous Pharmaceutical Manufacturing: From Molecule to Medicine through Connected Platforms, AI and Self-Driving Technologies
September 28 – 30 • 2026 • Ghent
Dear Colleagues,
we want to inform you that we have extended the abstract submission deadline to August 28. Take your chance and submit your abstract today!
We also want to remind you that the early bird registrations closes on June 30!
The 13th EuPAT Conference will bring together scientists, engineers, technology developers, and regulatory experts from academia and industry to explore the next generation of intelligent, integrated, and autonomous pharmaceutical development and manufacturing. The program will highlight how advanced manufacturing platforms—ranging from batch to continuous processes—combined with digitalization, automation, and end-to-end integration, are transforming the development and production of drug substances and products.
Through focused scientific sessions and a hands-on workshop, the conference will present cutting-edge research and real-world case studies on topics such as advanced PAT tools, innovative Quality by Design strategies, integrated development–manufacturing platforms, and the application of artificial intelligence across the pharmaceutical lifecycle. Particular emphasis will be placed on autonomous systems, self-driving laboratories, and emerging manufacturing concepts, alongside regulatory perspectives to ensure quality, robustness, and patient safety.
Registration and abstract submission
Registration and abstract submission is now open. Early bird rates apply until the 30th June and the extended abstract submission deadline will be 28th August.
All participants are encouraged to submit an abstract to share their latest research as a poster presentation.
From the submitted abstracts, selected scientists will be invited to deliver an oral presentation alongside the keynote speakers.
The abstract submission is now open.
Scientific Program
28th September – CESPE industry-focused session: PAT in Practice: Implementation Challenges, Measurable Impact and Real Outcomes
28th September – Workshop TBD
29th September – Session 1 Next-generation sensors, advanced PAT tools and innovative QbD strategies, supporting real-time monitoring, intelligent control and robust, flexible manufacturing across batch, mini-batch and continuous processes
29th September – Session 2 Integrated and autonomous pharmaceutical platforms, connecting drug substance and drug product development through end-to-end manufacturing
30th September – Session 3 Artificial intelligence across the pharmaceutical lifecycle, enabling predictive modeling, data-driven decision making and autonomous operation
Scientific and Planning Committee
Prof Jukka Rantanen, University of Copenhagen, Copenhagen DK (Chair EUFEPS QbD/PAT ST)
Prof Thomas de Beer, Ghent University, Ghent BE (Chair EuPAT 13)
Prof Jarkko Ketolainen, University of Eastern Finland, Kuopio FIN
Dr Daniel Markl, CMAC, University of Strathclyde, UK
Dr Natalie Maclean, CMAC, University of Strathclyde, UK
Dr Susanna Abrahmsén-Alami, AstraZeneca, SE
Dr Sandra Häberle, EUFEPS, Frankfurt DE
Dr Wim Oostra, Abbott, Weesp NL
Dr Jérôme Mantanus, UCB, BE